Carlsmed (CARL) Common Equity (2024 - 2026)

Carlsmed has reported Common Equity for 3 years, with the latest figure at $92.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 220.41% year-over-year to $92.2 million; the trailing twelve-month figure through Mar 2026 stood at $92.2 million (up 220.41% YoY), and the FY2025 full-year result was $98.9 million, up 239.98% from the prior year.
• Common Equity for Q1 2026 stood at $92.2 million, down from $98.9 million in the prior quarter.
• The five-year high for Common Equity was $106.7 million in Q3 2025, with the low at -$83.1 million in Q2 2025.
• Historically, Common Equity has averaged -$7.0 million across 3 years, with a median of -$61.9 million in 2024.
• The largest YoY upside for Common Equity was 261.54% in 2025 against a maximum downside of 43.88% in 2025.
• Carlsmed's Common Equity stood at -$70.6 million in 2024, then surged by 239.98% to $98.9 million in 2025, then retreated by 6.7% to $92.2 million in 2026.
• The last three Common Equity figures came in at $92.2 million (Q1 2026), $98.9 million (Q4 2025), and $106.7 million (Q3 2025), per Business Quant data.